Table 1 Summary of measurement
Outcome | Measurement tool | Details |
|---|---|---|
Primary outcome | ||
 Relapse rate | Psoriasis Area and Severity Index (PASI) score | Relapse defined as losing 50% of the improvement obtained from treatment once the treatment is stopped |
Secondary outcome | ||
 Time to relapse | PASI score | Time domain between achieving at least 50% reduction in PASI score and losing 50% of the improvement obtained from treatment once the treatment is stopped. |
 Time to new onset | PASI score | Time domain between lesion clearing and recurrence |
 Rebound rate | PASI score | Rebound defined as a severe and sudden change in the severity of psoriasis that is significantly worse than before the treatment was initiated |
 PASI improvement rate | PASI score | PASI score is a tool used to measure the severity and extent of psoriasis. It takes a few minutes and experience to calculate it accurately. A representative area of psoriasis is selected for each body region. The intensity of redness, thickness, and scaling of the psoriasis is assessed as none (0), mild (1), moderate (2), severe (3), or very severe (4) |
 VAS | Visual analog scale (VAS) | VAS is the most common pain scale for quantification of endometriosis-related pain. We use VAS to evaluate the feeling of pruritus in participants during the treatment period |
 BSA | Body surface area (BSA) | BSA is a common measure in the medical field and part of the complete body size and composition profile |
 DLQI | Dermatology Life Quality Index (DLQI) | DLQI is a dermatology-specific quality of life instrument. It is a simple 10-question validated questionnaire. At present, the DLQI is the most frequently used instrument in studies of randomized controlled trials in dermatology |